🌐 Also available in: 🇩🇪 Deutsch
Original source: World Medical Innovation Forum
This video from World Medical Innovation Forum covered a lot of ground. Streamed.News selected 8 key moments and summarises them here. Everything below links directly to the timestamp in the original video.
Understanding how brensocatib targets specific immune responses could open new avenues for treating chronic lung conditions. This new therapeutic could significantly improve outcomes for a large, underserved patient group.
New Drug Brensocatib Targets Neutrophil Activation in Non-CF Bronchiectasis
A new therapeutic, brensocatib, shows promise in treating non-cystic fibrosis (non-CF) bronchiectasis by inhibiting serine proteases, notably neutrophil elastase. The drug is expected to be most effective in patients with highly metabolically active neutrophils, which contribute to the disease's symptomatic activity. This represents the first medicinal therapeutic specifically targeting this patient population. This new treatment could address a significant, underserved market, potentially impacting 300,000 to one million people in the U.S. who suffer from non-CF bronchiectasis. While clinical experience is limited, the drug’s mechanism offers a novel approach to managing this complex condition, which has a wide array of underlying causes.
"This would be an opportunity for therapeutics and it's the first really medicinal therapeutic that's targeting the bronchiectasis population."
Winrevair Transforms Pulmonary Arterial Hypertension Treatment Paradigm
The introduction of Winrevair (sotatercept) has significantly reshaped the treatment approach for pulmonary arterial hypertension (PAH), moving towards disease modification rather than just symptom management. Clinical trials like Hyperion, Zenith, and Stellar demonstrate its efficacy when used as an add-on to existing stable background therapies, leading to dramatic patient improvement and enabling the de-intensification of other treatments over time. This shift allows for an initial multi-combination therapy strategy, akin to cancer treatment, where drugs are gradually reduced once positive results are achieved. While pulmonary vasodilators remain crucial for immediate relief, Winrevair's slow-acting, reverse-remodeling effect provides long-term benefits, fundamentally altering patient care.
"Winrevair has had a huge impact on how we manage patients. It's a whole new pathway which has opened the door for most of us in the field talking about disease modification."
Hyperion Study Confirms Winrevair Efficacy in Earlier PAH
The Hyperion study, evaluating Winrevair (sotatercept) in earlier stages of pulmonary arterial hypertension (PAH), was halted prematurely due to the overwhelming efficacy demonstrated in a more advanced disease trial (Zenith). Despite the early cessation, the results showed similar improvements in patients and a comparable side effect profile, affirming Winrevair's positive impact. This reinforces Winrevair's role in PAH treatment, although its use in earlier stages will still involve initial background therapy because those treatments act more quickly. The study confirms that Winrevair consistently delivers benefits across different disease progression points, even if the data from the early-stopped trial is somewhat diluted.
"We saw similar results of improvement, same side effect profile, same efficacy signal, but some of the data is a little bit dilute because we cut the study early, but it's still clearly a positive study."
INS MED's TPIP Praised for Convenience in Pulmonary Hypertension Treatment
INS MED's investigational once-daily treprostinil prodrug, TPIP, is being lauded for its potential to significantly enhance patient convenience and efficacy across various pulmonary hypertension (PH) conditions. Marin Waxman, a DSMB member, dismissed concerns raised by competitors regarding baseline walk data or conversion issues, underscoring the drug's anticipated broad application. The drug's ease of use and comparable efficacy to existing treprostinil treatments are expected to make it a transformative option for patients with PH, pulmonary hypertension with interstitial lung disease (PHILD), and pulmonary hypertension with COPD (PHCOPD). Its well-tolerated profile and reliable conversion to active drug are key advantages.
"To be able to take that drug once a day or twice a day…obviously it makes the world a whole lot easier for the patient. The drug is well tolerated. The efficacy I can't imagine will be any different from what we've seen with treprostinil."
Managing Cough Side Effect Key to Tyvaso Accessibility for IPF Patients
Nintedanib offers modest efficacy and significant gastrointestinal side effects in treating Idiopathic Pulmonary Fibrosis (IPF), similar to existing therapies. In contrast, inhaled treprostinil (Tyvaso), despite its primary side effect of cough, has extensive clinical experience demonstrating that this can be effectively managed. Practical strategies, such as using honey or specific inhalers, make Tyvaso accessible to most patients, allowing them to tolerate the treatment. This experience, spanning over a decade with Tyvaso in various lung conditions, suggests that tolerability, rather than efficacy alone, will be a crucial factor in the adoption of new IPF therapies.
"It's a rare patient that we can't get on the drug. And it's simple things. You can have them take some tea with honey, sometimes an inhaler, sometimes just a teaspoon of honey, and they can now inhale the drug."
Biologics Offer New Approach for Eosinophilic COPD Exacerbations
Biologics like dupilumab and mepolizumab are now being considered for COPD patients experiencing exacerbations despite inhaled therapy, particularly those with peripheral blood eosinophilia. These drugs represent a novel strategy to target specific "treatable traits" within the complex, syndromic condition of COPD. While effective in severe asthma, their efficacy in COPD is somewhat less pronounced. Dosing frequency and eosinophil threshold requirements vary between dupilumab (higher eosinophils, every two weeks) and mepolizumab (lower eosinophils, monthly), influencing patient adoption. This marks an exciting, albeit still evolving, addition to COPD treatment options.
"If we think about these drugs and how successful they've been in asthma and now being introduced into COPD, it starts us to think about the airway and thinking about treatable traits."
Inhaled Therapies Preferred for IPF Due to Localized Action
New therapies for Idiopathic Pulmonary Fibrosis (IPF) are expected to be used in combination regimens, as complex diseases necessitate multi-drug approaches. Inhaled treatments, such as treprostinil, are likely to be preferred over systemic drugs like nintedanib due to their localized action in the lungs. This localized delivery minimizes systemic side effects, allowing for better tolerability and more effective balancing of drug doses. The strategy emphasizes maximizing therapeutic benefit while reducing adverse reactions, a critical factor for long-term management of chronic conditions like IPF.
"I don't ever see us treating any of these diseases with just one drug. They're too complicated and any complex disease that we take care of whether it's heart failure, HIV, PH, they all warrant combination therapy."
Winrevair Bleeding Risks Plateau Over Time, Long-Term Data Confirms
Bleeding risks associated with Winrevair (sotatercept), primarily epistaxis (nosebleeds) and telangiectasias (spider veins), are common but tend to stabilize after initial treatment. Long-term data from the Soteria open-label extension study, now four years in, indicates no increased incidence of epistaxis over time. While nearly all patients develop telangiectasias, these are often cosmetic, and increased nosebleeds typically level off after six months to a year. This long-term safety profile is crucial for broader adoption of Winrevair in treating pulmonary arterial hypertension, reassuring both clinicians and patients about its sustained use.
"We're not seeing an increase in incidence of epistaxis. So it seems to plateau out. Same with the hemoglobin."
Summarised from World Medical Innovation Forum · 41:53. All credit belongs to the original creators. World Medical Innovatio Forum summarises publicly available video content.
